Media reports on deal for Queensland COVID-19 vaccine supply incorrect, says CSL

20 July 2020

The report by the Courier Mail and other Australia media agencies on Saturday that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect, says the country’s leading pharma company CSL Limited (ASX: CSL).

In response to the global health emergency, the Coalition for Epidemic Preparedness Innovations (CEPI), CSL and University of Queensland (UC) have partnered to accelerate the development and manufacturing of UQ’s COVID-19 vaccine candidate. This vaccine, which last week entered into Phase I clinical trials, is in the early stages of development.

In line with the Federal Minister for Health Greg Hunt’s comments, negotiations between CSL and the Australian government for a formal national supply agreement are ongoing. The Australian government provides a range of free vaccines through the National Immunization Program, based on expert medical advice.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK